Skip to main content
Premium Trial:

Request an Annual Quote

INDUSTRY BRIEFS: Jun 10, 2002

Premium

Micromass Licenses DIOS-MS Technology from Scripps Research Institute

Micromass said last week that it has licensed DIOS (desorption ionization on silicon) technology from Gary Siuzdak, the director of the Center for Mass Spectrometry at the Scripps Research Institute in La Jolla, Calif., for use as an alternative ionization platform to MALDI. The exclusive license is designed to support ongoing research at Scripps for applying the matrix-free technology to mass spectrometry analysis of protein and low-molecular-weight species, the company said. Micromass will own rights to downstream revenue from the technology, which was initially published in the May 20, 1999, issue of Nature. Because the DIOS-MS method does not rely on a matrix to aid in ionization, Micromass said the technology could potentially aid in the analysis of low-molecular-weight species that often get lost in the noise attributed to the MALDI matrix.

Phylos Teams With Upstate to Develop Protein Chip

Phylos is working with Upstate to develop binding protein reagents for a new protein chip, the company said last week. Under the arrangement, Upstate will market the chip, and Phylos will receive research funding and milestone payments and royalties, if applicable. Upstate, based in Waltham, Mass., develops drug discovery reagents, kits, and services based on cell signaling. It sells kits for kinase activity screening and for Luminex’s detection system.

HUPO and Amersham Hit the Road for Proteomics

HUPO and Amersham Biosciences kicked off a joint North American and European tour last week to discuss new research in proteomics and educate researchers about the recent advances and new technologies in the field. The summer road show began last week at Yale University.

Amersham Applications Manager Reiner Westermeier will discuss using mass spectrometry and 2D-gel electrophoresis in proteome analysis. HUPO representatives will also give updates on organization projects. From June 3 to June 14, researchers will visit universities and hotel conference centers in Piscataway, NJ; Quebec City; Montreal; Toronto; Ann Arbor, Mich.; Minneapolis; Denver; Salt Lake City; and San Francisco. HUPO presenters will include organization president Sam Hanash, University of Louisville’s Peipei Ping, University of Texas Southwestern’s Yingming Zhao, University of Michigan’s David Beers, and the Van Andel Institute’s Brian Haab. The seminar is free. For further information, visit www.amershambiosciences.com.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.